Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety With the Transdermal Contraceptive System.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women with regular menstrual cycles~* sexually active and at risk of pregnancy~* nonpregnant~* acceptable body mass index (BMI)~* last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since~* sitting BP\<140mmHg/\<90mmHg~* 1 normal menstrual cycle since removal of IUD or norplant~* agreement to use study drug for contraception for up to 13 cycles, except when backup contraception is required for disease protection or patch detachment~* agree not to use other systemic steroid medication~Exclusion Criteria:~* Presence, history, hereditary predisposition or risk of deep vein thrombophlebitis or thromboembolic disorders~* cerebral vascular or coronary artery disease, hypertension, or severe migraines~* liver tumor resulting from estrogen-containing products~* diabetes mellitus~* cholestatic jaundice, liver or renal disease~* abnormal PAP smear~* thyroid disorder~* dermal hypersensitivity~* carcinoma of breast, endometrium or other estrogen-dependent neoplasia~* substance abuse~* received experimental drug within prior 30 days~* smoking women over 35 years of age.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).